mobocertinib for previously treated nsclc with efgr mutations
Published 3 years ago • 555 plays • Length 1:42Download video MP4
Download video MP3
Similar videos
-
2:03
amivantamab and lazertinib in treatment-naïve egfr-mutant nsclc
-
1:46
the evolving treatment landscape for nsclc with egfr exon 20 insertion mutations
-
1:05
efficacy of mobocertinib in patients previously treated with tkis
-
1:25
current treatment recommendations and future directions for egfr-mutant nsclc
-
3:51
wu-kong1: sunvozertinib in nsclc with egfr exon 20 insertion mutations
-
6:17
asco 2021 lung recap: amivantamab and mobocertinib for egfr exon 20
-
0:52
targeted treatments for egfr exon 20 insertion mutations in nsclc
-
2:03
nsclc with egfr exon 20 shows benefit with mobocertinib over chemotherapy
-
3:58
current treatments and challenges for patients with egfr exon 20 insertion-positive nsclc
-
2:23
therapeutic strategies for egfr-mutated lung cancer
-
3:34
repeat biopsy in lung cancer patients with egfr mutation
-
1:21
detectability of uncommon egfr mutations in nsclc: ngs versus pcr
-
1:56
recent approvals in the nsclc treatment landscape
-
4:37
advances in efgr-mutant nsclc treatment
-
2:45
activity of egfr tkis in patients with nsclc with uncommon egfr mutations
-
1:18
amivantamab for nsclc with met exon 14 skipping mutations
-
3:49
zenith20: poziotinib in egfr and her2 exon 20 mutant nsclc
-
3:17
phase iii mariposa: amivantamab lazertinib vs osimertinib in egfr-mutated nsclc
-
5:03
understanding nsclc treatment when you have an egfr mutation